Effects of oxycodone pharmacogenetics on postoperative analgesia and related clinical outcomes in children: a pilot prospective study.
Blessed Winston AruldhasSara K QuinneyBalachundhar SubramaniamBrian R OverholserOlivia RaymondSahana SivamInesh SivamSanjana VeluAntoinette MontelibanoSenthilkumar SadhasivamPublished in: Pharmacogenomics (2023)
Background: Variability in the pharmacokinetics and pharmacodynamics of oxycodone in children undergoing surgery could be due to genetic polymorphisms. Materials & methods: The authors studied the association between clinical outcomes and pharmacogenes in children undergoing major surgery. A total of 89 children (35 undergoing pectus excavatum repair and 54 undergoing spinal fusion) were recruited. Results: OPRM1 SNP rs6902403 showed an association with maximum pain score and total morphine equivalent dose (p < 0.05). Other polymorphisms in OPRM1 SNP, PXR , COMT and ABCB1 were also shown to be associated with average morphine equivalent dose, length of hospital stay and maximum surgical pain (p < 0.05). Conclusion: This study demonstrates novel associations between the above pharmacogenes and oxycodone's pharmacokinetics as well as postoperative outcomes in children. Clinical trial registration : NCT03495388 (ClinicalTrials.gov).
Keyphrases
- young adults
- clinical trial
- minimally invasive
- chronic pain
- pain management
- healthcare
- patients undergoing
- randomized controlled trial
- metabolic syndrome
- type diabetes
- emergency department
- adipose tissue
- coronary artery disease
- spinal cord injury
- skeletal muscle
- neuropathic pain
- acute coronary syndrome
- percutaneous coronary intervention
- surgical site infection
- weight loss
- phase ii
- double blind